Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple supplement boost sperm health and IVF success?

NCT ID NCT07800052

Disease control Sponsor: Kocaeli University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether a three-month course of the dietary supplement Stemregen can improve sperm quality in men with severe oligoasthenozoospermia, a condition marked by very low sperm count and poor movement. Researchers will compare semen parameters, sperm DNA damage, and outcomes of intracytoplasmic sperm injection (ICSI) between men taking the supplement and a control group. The goal is to see if the supplement can enhance fertility treatment success after previous failed attempts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stemregen, a dietary supplement
What this could lead to
If it works, this supplement could offer a simple, non-invasive way to improve sperm quality and increase the chances of success in IVF for men with severe infertility.
What could go wrong
This is a small, non-randomized study, so results may not be conclusive. The supplement's effect on sperm and pregnancy outcomes is uncertain, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Oct 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 50 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:men aged 20-50 years with severe oligoasthenozoospermia, defined for the purposes of the study as a sperm concentration \<5 × 10⁶/mL with markedly reduced progressive motility, and at least one previous unsuccessful intracytoplasmic sperm injection (ICSI) cycle. - Exclusion Criteria:clinically significant varicocele requiring surgical correction, obstructive azoospermia, hypogonadotropic hypogonadism, primary testicular failure, chromosomal abnormalities or known genetic causes of infertility, active genitourinary infection, uncontrolled diabetes mellitus, severe systemic disease, malignancy, previous chemotherapy or pelvic radiotherapy, and hormonal or antioxidant treatment within the preceding three months. Female partners underwent routine infertility evaluation, and couples with severe female infertility factors, including diminished ovarian reserve, advanced endometriosis, major uterine abnormalities, or severe ovulatory dysfunction \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Male infertility are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

male infertility oligoasthenoteratozoospermia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Male infertility Oligoasthenospermia

Contacts and locations

Locations

  • Kocaeli Unversity Hospital

    Köseköy, Kocaeli, 41001, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.